Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infecte...( --Addition of New Study Site at Lea...),Health

--Addition of New Study Site at Leading Urban Medical Center Will Expand the Eligible Patient Pool for the Ongoing Bavituximab HCV/HIV Co-Infection

Trial-- --Dr. Sulkowski, Principal Investigator of The Johns Hopkins Study Site,

Has Expertise in Studying HCV Infection in HIV Patients--

TUSTIN, Calif., Nov. 26 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced the addition of The Johns Hopkins Hospital in Baltimore, Maryland to its ongoing clinical trial designed to evaluate the safety and pharmacokinetics of bavituximab in patients co-infected with HCV and the human immunodeficiency virus (HIV). The trial will be conducted under the direction of Dr. Mark Sulkowski, associate professor of medicine in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine. Patient dosing is continuing in the bavituximab HCV/HIV co-infection study at Saint Michael's Medical Center in Newark, New Jersey.

Dr. Sulkowski is a co-investigator for the Johns Hopkins University AIDS Clinical Trials Unit and has served as the principal investigator for numerous clinical trials related to the management of HCV in persons with and without HIV co-infection. Dr. Sulkowski has also co-authored several medical papers on HCV patients infected with HIV.

"We expect that this new study site for the bavituximab co-infection trial will be a valuable addition to our efforts to ensure that enrollment in the trial proceeds as planned," said Steven W. King, president and CEO of Peregr
'/>"/>